Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
Key facts
- Who runs it
- OHSU Knight Cancer Institute
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 4 people enrolled
- Started
- 1 Mar 2023
- Ended
- 10 Jul 2024
- Type of study
- Interventional
- Treatments tested
- Botulinum Toxin Type A
- Record updated
- 13 May 2025
- Why it stopped
- low enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Participant scheduled for elective distal pancreatectomy or radical antegrade modular pancreatosplenectomy (RAMPS), via open or laparoscopic technique
- Participant >= 18 years of age
- Ability to understand nature and individual consequences of clinical trial
- Written informed consent from participant or legally authorized representative
- For participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention
Who cannot take part
- Prior BTX administration
- Known hypersensitivity to any BTX preparation or to any of the components in the formulation
- Infection at the proposed injection site, including cholangitis
- Serious cardiovascular disease (e.g., myocardial infarction in the past year, New York Heart Association [NYHA] III/IV congestive heart failure, unstable angina)
- Neuromuscular or any neurological disease with associated increased risk for a participant undergoing BTX injection
- Any condition that could result in undue risk for the participant and/or influence outcome measures (in the opinion of the investigator)
- Creatinine clearance < 30 mL/min
- Anatomy incompatible with planned intervention (e.g., Roux-en-Y gastric bypass, distal gastrectomy with Roux-en-Y or Billroth II reconstruction)
- Acute pancreatitis within 2 weeks of planned study intervention
- American Society of Anesthesiologists (ASA) score > III
- Liver cirrhosis (of any Child-Pugh grade)
- Inability to obtain informed consent due to comprehension or language barrier
- Inability to comply with study and/or follow-up procedures
- Pregnancy or lactation
Where in United States
- OHSU Knight Cancer InstitutePortland, United States
About the trial
What the trial wants to find out
This phase II trial studies the effect of botulinum toxin (Botox) in preventing postoperative pancreatic fistula after distal pancreatectomy. Postoperative pancreatic fistula (POPF) is a known risk of distal pancreatic surgery, in which leakage of pancreatic digestive liquids causes internal swelling that can be painful (termed inflammation). A valve-like muscle, called the Sphincter of Oddi, opens and closes, controlling the flow of digestive liquids from the liver (bile) and pancreas (pancreatic juice) to the small intestine (duodenum). After surgery, the Sphincter of Oddi may act to block the flow of normal pancreatic secretions, causing secretions to leak into the abdomen resulting in POPF. Botox is a drug that can cause paralysis of muscles. Giving an injection of Botox into the sphincter of Oddi before distal pancreatic surgery may reduce leakage of digestive fluids and potential POPF.
The group in the trial
- Treatment of POPF (botulinum toxin type A)Treatment being tested
Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter of Oddi segment between 7-14 days prior to planned distal pancreas resection.
Treatment: Botulinum Toxin Type A
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Trial of Pre-Operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
- Record updated
- 13 May 2025